# CytoDyn Inc.: overview CYDY · OTC · CIK 1175680 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31 Pages: [Overview](/companies/cydy.md) · [Financials](/companies/cydy/financials.md) · [Filings](/companies/cydy/filings.md) · [Insiders](/companies/cydy/insiders.md) Latest reported revenue: [$0](/filings/0001558370-23-015718.md) for Q4 FY2022, three months to 2022-05-31, from the 10-K filed Sep 14, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-23-015718). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [0.00](/filings/0001175680-26-000035.md) | [(0.02)](/filings/0001104659-26-002335.md) | [0.00](/filings/0001104659-26-040687.md) | not reported | [(0.01)](/filings/0001175680-26-000035.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [266](/filings/0001558370-23-015718.md) | [0.0](/filings/0001558370-23-015718.md) | not reported | not reported | not reported | | Gross margin | % | [80.1%](/filings/0001558370-23-015718.md) | not reported | not reported | not reported | not reported | | Operating margin | % | [(54663.2%)](/filings/0001558370-23-015718.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(79255.6%)](/filings/0001558370-23-015718.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.31)](/filings/0001558370-23-015718.md) | [(0.10)](/filings/0001558370-24-012328.md) | [(0.05)](/filings/0001558370-25-009617.md) | [0.00](/filings/0001175680-26-000014.md) | [(0.03)](/filings/0001175680-26-000014.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cydy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DIVERSIFIED TRUST CO](/funds/1479844.md) | 2026-06-30 | $10.9k | 45,790 | | Unchanged | | [Williams Jones Wealth Management, LLC.](/funds/1788587.md) | 2026-06-30 | $10.7k | 45,001 | | Unchanged | | [Next Capital Management LLC](/funds/1752762.md) | 2026-06-30 | $6.0k | 25,000 | | Unchanged | | [HORIZON FINANCIAL SERVICES, LLC](/funds/1674020.md) | 2026-06-30 | $4.3k | 18,200 | | Unchanged | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $2.3k | 9,488 | | Unchanged | | [CAZ INVESTMENTS LP](/funds/1159363.md) | 2026-06-30 | $955 | 4,000 | | Unchanged | | [CAZ INVESTMENTS LP](/funds/1159363.md) | 2026-06-30 | $955 | 4,000 | | Unchanged | ## Recent filings [All 1,283 filings](/companies/cydy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:50 ET | [8-K](/filings/0001175680-26-000038.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001175680-26-000038 | | 2026-10-14 | 12:33 ET | [10-Q](/filings/0001175680-26-000035.md) | Quarterly report, period 2026-08-31 | 0001175680-26-000035 | | 2026-09-28 | 20:48 ET | [DEF 14A](/filings/0001175680-26-000026.md) | Proxy statement, period 2026-09-28 | 0001175680-26-000026 | | 2026-08-31 | 12:31 ET | [10-K](/filings/0001175680-26-000014.md) | Annual report, period 2026-05-31 | 0001175680-26-000014 | | 2026-04-30 | 20:32 ET | [8-K](/filings/0001175680-26-000002.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001175680-26-000002 | | 2026-04-22 | 21:21 ET | [S-1](/filings/0001104659-26-046921.md) | Registration statement | 0001104659-26-046921 | | 2026-04-08 | 12:30 ET | [10-Q](/filings/0001104659-26-040687.md) | Quarterly report, period 2026-02-28 | 0001104659-26-040687 | | 2026-03-24 | 21:15 ET | [8-K](/filings/0001104659-26-033943.md) | 1.01 Entry into a material agreement | 0001104659-26-033943 | | 2026-03-05 | 13:35 ET | [8-K](/filings/0001104659-26-023856.md) | 3.02 Unregistered sale of equity | 0001104659-26-023856 | | 2026-01-09 | 13:30 ET | [10-Q](/filings/0001104659-26-002335.md) | Quarterly report, period 2025-11-30 | 0001104659-26-002335 | ## Latest annual report [Form 10-K for the fiscal year ended May 31, 2026](/filings/0001175680-26-000014.md), filed Aug 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1175680 - Tickers: CYDY - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.